Keep calm, no major changes. PC is going to cover their local specialists. This similar to former footprints of the past. Specialty will moved into pcp for diabetes and will minimize disruptions to endocrinologists. There is simply not enough endos to have two specialty representatives cover massive territory when PCP is in place in most markets. PCP 1 and 2 will go back to cover internists and endocrinologists in their local market.
Any changes for us over here promoting Praluent. Any change in headcount in CV? Are they bringing back primary care reps after letting PC1 & PC2 reps go over the last year and a half?
So right now we have 10 people in our district. 4 pods of 2 PC and then 2 SP that cover the entire district. If this is true, we dissolve SP into PC and then 2 PC are restructured out? Are we then back to a district of just 8 reps or do districts get bigger? Please don’t tell me we are going back to tiny teams of 6-8 reps in a district with weekly or biweekly field days! Ugh!
In regards to CV specifically, there are three scenarios depending upon FDA decision on outcomes and upcoming litigation. If litigation and outcomes comes out in favor of the organization an expansion of PCP will be minor. Until breakeven threshold is met there will be no changes. Any expansion would include diabetes PCP/SP picking up Praluent in a tertiary position focusing on samples and reimbursement. If things do not pan out in our favor the ball will be thrown to Regeneron and they will decide head count.
20y word on MS or Rare? Lemtrada sales are tanking. And BW is clueless and ruining moral. Are layoffs in the plans for 2019?
You have it backwards my friend. There isn’t enough Soliqua to justify so many reps. Managers will be getting huge territories (so massive cuts there) and primary care going bye bye. They have t generated scripts from their targets just getting paid off scripts specialty generates. Look to see one possibility two primary care reps being added to specialty with the rest cut. Don’t drink the kool aid management is serving now that there won’t be cuts and we are too thin. Complete bullshit the cuts are coming and it will be a blood bath again. Good luck all
I agree we are not too thin for this environment and our products. However, let’s not start a repeat of the Praluent argument PC getting paid on specialty scripts. Yes, a bulk of the Toujeo scripts do come from endos. However they’re also the ones killing us - down week over week while our NP’s, PA’s, FP/IM are growing. With Soliqua, we are over 120% of goal and that’s is predominately PC targets. The endos don't like it. We get folks writing Soliqua and then the next Qtr. they become SP targets. So I do see how PC could go away, but then the existing SP team becomes the new PC team, while still calling on Endos? Just trying to make sense of all this.
Praluent PC reps getting credit for all dirt was nothing more than stealing. The Praluent PC team was the laughing stock of the company. Never saw more useless reps in my career. Getting paid bonus dollars for having zero impact in cardiology.
oh boy...here comes the crying whining special rep complaining that the PC reps are horrible. Everyone knows that the PC force drive referrals to the cardiologists and lipidologists. This guys is crying because his performance is/was lacking. Gotta point the finger at someelse. The ole “pot calling the kettle black “. Hey buddy, look in the mirror and you’ll find the problem. Now go get me some Praluent scripts, boy.
you are a fucking moron, PC never did and never will drive this market through referrals. stupidest fucking argument i ever heard from what was a worthless PC praluent sales force period!!
Please people, let’s not get into this again. PC Praluent is gone...let’s move on. However, there are lots of diabetes folks out there with questions. Can we get back to the topic on hand with this? Are we back to waiting for a call the Monday after Thanksgiving? It’s been awhile since we’ve played that game.
Again I’m only providing the knowledge I have. Footprint is going back 2 reps for most territories that will cover local endocrinologists. Whether this means primary cares or specialty reps survive is based on numerous factors. Soliqua has very few endocrinologists support and due to the simple number of endocrinologists in most markets is small and will be handled by local representatives. Good luck to all.
Listen up Sherlock, your problem is not with PC. The problem is you and Sanofi who is about to put their proverbial boot on the back of your neck. Get a clue and a life and you’ll be better off. Oh, and one more thing, don’t overextend your finances on xmas gifts. After you get canned, money is going to be tight. I would invest in a better attitude. You’ll need it for future job interviews, after thanksgiving.
PC Praluent never did drive referrals to specialists. This was something PC Abl and RBL's and PC reps kept repeating to justify their jobs. They did nothing. Amgen crushed them in PC. Stop making yourself look stupid. Hopefully if a sales team comes back to PC Praluent they will get paid only on PC targets.
This is the same old tired thinking from the specialty division. They know good and well that 90% of all patients seeking cardio care are being referred from FP and IM. That’s how it works folks. Everyone knows that Amgen counted their free drug (pap) in their PC #s. So give it a rest, will ya? You’re starting to embarrass yourself. Stupid is stupid does, you fool.
You really are clueless. No doubt a layed off PC rep. 90% of card scripts come from patients they've been treating for years . Maybe 10% and that's generous were send to card fromPC. That's day to day. If you spent anytime in a card office and talked with Ma's and nurses you soon find out it's a patient of theirs. Stop making out that PC was some sort of gladiator school for Praluent . You earned a bonus check for doing nothing . You needed to be cutting your specialty reps yard, washing his car, weeding his grass and cleaning his pool. Just being real. If PC was such the driver then why are they on the outside looking in now??
Give it up folks! We are so sick and tired of this SP vs PC argument. The bottom line is, you are part of Sanofi DCV. Diabetes has been set up that way for years. Deal with it and stop your bickering. For heaven’s sake, there is NO CV PC at this time anyway. The real question is... who buys into the repeated comment “ no restructuring planned going into the beginning of next year?” Not too sure about what that actually means anyway. Possibly a restructuring in Q1? This is what someone Inside 55 could help with.
